Rating: Neutral | Target Price: RMB 20–22 (base-case fair value range) | Current Price: RMB 19.48 (close, 2026-10-29) | Margin of safety: ~+3% (vs. lower bound of base-case fair value) | Time horizon: 12 months | Market cap: RMB 53.57 billion (2.750 billion shares) | Sector: Basic Chemicals – Coal Chemicals
Hualu Hengsheng is the platform-type leader at the far left of the coal chemical industry's cost curve (per sell-side research): in 2025, while most industry peers posted losses, it still achieved net profit attributable to shareholders of RMB 3.315 billion, with non-recurring items accounting for less than 1% of net profit, and operating cash flow covering net profit at no less than 1.09x for four consecutive years. Earnings entered a recovery phase in 2026 (attributable net profit +33.6% for the first three quarters), but Q3 single-quarter growth fell sharply to +1.63%, with gross margin down 6.5 percentage points quarter-on-quarter; combined with rising coal prices in October and weakening urea spot prices, the sustainability of the recovery has become the focal point of the bull-bear debate. The current price of RMB 19.48 corresponds to 1.53x PB (near a 10-year low percentile) and 13.07x PE (TTM) (around the 5-year median). Back-solving from an EV perspective implies normalized earnings of roughly RMB 4.0–4.4 billion, 12%–21% below the sell-side consensus at the freeze date (RMB 4.81 billion) — the market is pricing a middle ground between "recovery persists" and "boom fades," making it reasonably cheap rather than deeply oversold. The three-scenario distribution is right-skewed (bear -31%/bull +46%; probability-weighted fair value ~RMB 21.0, +7.8% vs. current price), but the margin of safety is thin and Q4 spread validation has yet to materialize: we recommend tracking it as a core-position value anchor, with any addition to the position awaiting the 2026 annual report's test of Q4 single-quarter attributable net profit (≥ RMB 1.0 billion as the base-case validation line; < RMB 700 million as the downturn confirmation line).
Key evidence:
Platform-type poly-generation kept the company at RMB 3.3 billion-level profits and a 10.3% ROE in 2025 despite industry-wide losses — a cyclical validation of its cost position. But two constraints must be noted simultaneously: first, the quantitative evidence for "far left of the cost curve" (industry-lowest per-ton ammonia cost) mainly comes from sell-side research, lacking corroboration from independent third-party audits or industry cost percentile data; second, the 2025 profit maintenance partly benefited from an 18% YoY decline in raw coal procurement prices, and this round's bottom ROE (10.32% in 2025, weighted annual-report basis) was below the previous bottom (12.1% in 2020) — the rise in absolute profit is largely attributable to asset scale expansion from the Jingzhou base coming onstream, and the "rising with each cycle" pattern on an ROE basis does not hold. This report's contrarian scenario: if the coal price center shifts higher and product prices cannot keep pace, the hedging capacity of the "far left" position will be weakened (already demonstrated in 2026Q3).
Key evidence:
The +33.6% recovery in the first three quarters was mainly spread-driven; acetic acid ASP +23.5% is already at the upper end of the RMB 2,390–4,250/ton range, so upside potential is smaller than downside risk; weakening urea spot prices plus high industry operating rates constitute supply pressure. To be balanced: the QoQ decline in Q3 gross margin to 17.62% included a one-off drag from ~20 days of shutdown maintenance, and 6 of 7 major products saw YoY price increases; rising coal prices also raise oil-based route costs more sharply, which actually highlights coal chemicals' relative cost advantage (management's view). This report therefore judges: Q4 single-quarter attributable net profit of RMB 930 million–1.08 billion (full year RMB 4.10–4.25 billion) is the neutral path, while the freeze-date consensus of RMB 4.81 billion implies Q4 needs +74% — hard to achieve. That consensus sample was largely formed before the Q3 disclosure, and the downward revision channel (-25.8% over the past 90 days) has not closed.
Key evidence:
The divergence between PB 1.53x and PE 13.07x percentiles needs explanation: TTM earnings include the 2026 geopolitical-conflict spread windfall, so the low PE percentile reflects the earnings denominator, not cheap pricing; the low PB percentile combined with a 10%–13% mid-cycle ROE band is the primary anchor for cyclicals — ROE/cost-of-equity implies a fair PB of ~1.15x, with the current 1.53x premium supported by growth assets (Jingzhou + new capacity). On implied expectations: back-solving from EV (ke 9.5%, perpetual growth +2.4%), the current price implies normalized earnings of ~RMB 4.0–4.4 billion, or ~RMB 3.8 billion on an equity market cap basis (sensitivity of ~±8%–9% per ±50 bps in ke) — 12%–21% below consensus but ~28% above Q3 annualization (RMB 3.26 billion). In one sentence: the current price requires the company to sustain ~RMB 4.2 billion in earnings, while sell-side is calling for RMB 4.8 billion and Q3 trend annualization is RMB 3.26 billion — the price sits in the middle.
Key evidence:
The evidence strength for growth vehicles is clearly stratified: Jingzhou ramp-up and gasification platform startup are realized facts; Dezhou's +750,000-ton urea expansion is backed by environmental approval with a relatively certain timeline; the 300,000-ton TDI project is still at environmental application and equipment tendering stages, and the "RMB 600–700 million annualized net profit at full capacity" figure is only Zhongtai's unilateral estimate — 300,000 tons represents roughly 20% of domestic TDI existing capacity as a supply increment, production is expected around early 2028 (outside this report's 12-month window), and the industry supply normalization risk at startup is not covered by that estimate. On valuation, measured against a zero-growth EPV at ke 9.5% (~RMB 10.5/share), option value beyond zero growth accounts for ~46% of the current price; using the upper end of the EPV range (RMB 14.6, with more generous discounting and higher cash flow assumptions), it accounts for ~25% — this residual includes both TDI/urea capacity growth and the recovery component of spreads normalizing to mid-cycle, with realization dependent on the cycle cooperating.
Key evidence:
The company maintained ~32% payout ratio + buybacks + no equity financing during the earnings downturn, and the controlling shareholder's holding was verified consistent with the theoretical post-bonus figure (prior doubts do not hold) — governance is clean. But the cash flow structure warrants caution: 2025 FCF was only RMB 548 million, below the RMB 1.225 billion combined dividends + buybacks, with the RMB 677 million gap covered by additional debt; the TDI project (total investment RMB 5.488 billion) means a capex rebound in 2027–2028 is a given, and management responded to questions about dividend and capex pacing over the next three years only with "coordinated arrangements," without quantified commitments. In addition, the recovery of the RMB 658 million litigation settlement net loss (~20% of 2025 attributable net profit) remains uncertain, directly affecting free cash flow and dividend capacity. If earnings fall into the bear-case range (RMB 2.7–3.0 billion), maintaining the current return level would require continued leverage increases.
| Metric | 2023FY | 2024FY | 2025FY | 2026Q1-3 |
|---|---|---|---|---|
| Revenue (RMB 100M) | 272.60 | 342.26 | 309.69 | 262.63 |
| Revenue YoY | -9.87% | +25.55% | -9.52% | +11.51% |
| Net profit attributable to shareholders (RMB 100M) | 35.76 | 39.03 | 33.15 | 31.71 |
| Attributable net profit YoY | — | +9.14% | -15.04% | +33.58% |
| Non-GAAP attributable net profit (RMB 100M) | 37.03 | 38.70 | 32.88 | 31.60 |
| Gross margin | 20.85% | 18.71% | 19.16% | 21.86% (Q3 single quarter 17.62%) |
| Net margin (attributable basis) | 13.12% | 11.40% | 10.71% | 12.07% |
| Operating cash flow (RMB 100M) | 47.15 | 49.68 | 41.98 | 34.61 |
| Free cash flow (RMB 100M, OCF-CapEx) | -39.95 | -1.13 | +5.48 | +10.02 |
| Cash and equivalents (RMB 100M, period-end) | 20.41 | 13.98 | 20.85 | 27.43 (2026-09-30) |
| Interest-bearing debt (RMB 100M, period-end) | 78.43 | 94.69 | 109.53 | 111.29 (2026-09-30) |
| Debt-to-asset ratio | 30.90% | 29.64% | 28.52% | 27.24% |
| Weighted ROE | 12.81% | 13.05% | 10.32% | 9.21% (first three quarters, not annualized) |
Reasons for metric changes (YoY ≥ ±20% excerpts, all per management's explanations):
First-three-quarters revenue RMB 26.263 billion (+11.51%), attributable net profit RMB 3.171 billion (+33.58%), non-GAAP RMB 3.160 billion (+34.16%) — but growth was entirely concentrated in H1: Q1 attributable net profit RMB 1.117 billion (+57.96%), Q2 RMB 1.236 billion (+43.95%), Q3 only RMB 818 million (+1.63%); Q3 single-quarter gross margin of 17.62% was down 6.5 percentage points QoQ from H1's 24.10%. The decline has three causes: ① from September 8, one coal gasification unit and some product units were shut down for maintenance for ~20 days (revenue impact ~RMB 230 million), with production resuming on September 29; ② raw coal/benzene/propylene procurement prices turned up YoY (Q3 raw coal range rose to RMB 660–1,100/ton); ③ prices of acetic acid and other products rose YoY but are already at the upper end of their ranges. By product, all four major segments saw volume and price gains in the first three quarters: new materials sales volume 2.5828 million tons at an average price of ~RMB 5,635/ton (+8.7% vs. FY2025 average), fertilizers 4.0373 million tons at ~RMB 1,395/ton (+9.8%), acetic acid 1.0923 million tons at ~RMB 2,677/ton (+23.5%), organic amines 398,400 tons at ~RMB 4,583/ton (+13.7%). Comparative judgment: first-three-quarters annualization of ~RMB 4.2 billion vs. Q3 single-quarter annualization of only RMB 3.26 billion — this huge scissors gap between the two measures is the quantitative expression of the current market debate; this report's full-year forecast of RMB 4.10–4.25 billion sits in the upper-middle range between the two (Q4 post-maintenance restart + gasification platform cost reduction + winter stocking peak season support sequential recovery, but rising coal prices cap the upside).
Model in brief: Asset-heavy coal-chemical platform — clean coal gasification (slurry-phase pressurized gasification) → syngas → synthetic ammonia/methanol → 40+ products via "one head, multiple lines" flexible co-production, with dual bases in Dezhou and Jingzhou. 100% of revenue comes from bulk chemical sales; no subscription/recurring revenue and overall no pricing power (prices fluctuate with coal prices and supply-demand), but structural bargaining power exists: world's largest DMF producer (~26% share), 50%+ domestic market share in methylamines, #1 in acetic acid nationally (9.6%), ~45% in oxalic acid, and #1 national capacity in DMC — its flexible switching capability allows the company to shift product mix on the same syngas platform based on profitability, maximizing gross margin retention.
Cash content of earnings: OCF/net profit attributable to parent of 1.32/1.27/1.27/1.09 over four consecutive years — excellent receivables quality; FCF/net profit of -1.12/-0.03/+0.17/+0.32 (9M2026). The negative figures in 2023–2024 were due to the Jingzhou Phase I capex peak (RMB 8.71 billion), turning positive from 2025 — the conversion of book profit into deployable cash has passed its inflection point, but 2025 FCF (RMB 548 million) still fails to cover the RMB 1.225 billion of dividends + buybacks. The gap between adjusted (ex-non-recurring) and attributable net profit has stayed below 1% in all years, with no one-off gain/loss dressing; the company reports no Non-GAAP adjustments (no aggressive items like SBC add-backs).
Return on capital: ROIC estimated at ~10.3% for FY2024 → ~8.4% for FY2025 (NOPAT RMB 3.88 billion / invested capital RMB 46.1 billion), in the 8%–10% range — below the ">15%" strong-signal line for a true moat, mainly due to dilution from Jingzhou's new assets entering depreciation early; against the historical band of weighted ROE (10.3% at this cycle's trough, 25.58% at the 2022 peak), returns are highly cyclical.
Capex quality: CapEx declining from RMB 8.71 → 5.08 → 3.65 billion (RMB 2.46 billion in 9M2026), with CapEx/depreciation falling from 4.7x to 1.17x; projects under construction (gasification platform RMB 3.039 billion, TDI RMB 5.488 billion) are growth expenditures; maintenance capex is not separately disclosed and cannot be precisely split, but the gasification platform's "replace old with new, cut energy consumption by another 5%" combines both maintenance and efficiency attributes.
Red flags and concentration: ① Supplier concentration doubled in three years (top five: 20.04% → 37.30% → 42.66%, strategic coal procurement concentrated); ② Low customer concentration (top five: 12.7%); ③ Surge in bank-acceptance bill collections (receivables financing +73.9%); ④ Minority shareholders take 30% of Jingzhou profit (9M2026 minority interest of RMB 280 million, 8.1% of net profit).
Follow-through: partially delivered. Revenue guidance history: 2024 guidance RMB 34.0 billion → actual 34.226 billion (delivered); 2025 guidance RMB 34.7 billion → actual 30.969 billion (missed by 10.7%, due to worse-than-expected industry price declines); 2026 guidance RMB 33.5 billion → first three quarters 26.263 billion (78.4% completed, on pace). Project execution is a strength: Jingzhou Phase I started production on schedule in November 2023 and ramped over three years (net profit RMB 155 → 919 → 1,134 million), and the gasification platform upgrade was built and commissioned in about 13 months. At earnings calls, key questions on urea prices, carbon quotas, and capex/dividend pacing over the next three years were all answered with "as per overall arrangement / subject to announcements" — quantitative guidance remains weak.
Shareholder friendliness: friendly. Payout ratio FY2023 35.6% → FY2024 32.6% → FY2025 31.92%; interim dividends normalized from 2024 (2026 interim again RMB 0.26/share, totaling ~RMB 715 million), cumulative dividends of RMB 3.606 billion over the past three years; FY2025 buyback of RMB 167 million, all cancelled; no equity financing (placements/rights issues/convertibles) in the past three years. Note: 2025 dividend cash coverage showed a shortfall of RMB 677 million (covered by added debt); sustainability depends on earnings and capex pacing.
Risk signals: ① Net charge of RMB 658 million from litigation settlement (melamine trade secret dispute: court-ordered deduction of RMB 218 million + settlement compensation of RMB 380 million + technology license fee of RMB 60 million); recovery efforts have entered enforcement proceedings but outcomes are uncertain, and this item was not quantitatively disclosed in the "Material Litigation" section of periodic reports (in 2025, RMB 98 million of litigation-frozen funds were released); ② Related-party transactions are controllable but persistent (guarantee fee rate of 0.3% on controlling shareholder loans, annual cap RMB 36 million; pro-rata capital injections into Jingzhou with related parties); ③ Governance changes: in 2025 the supervisory board was abolished and an employee director added; executive pay includes 30% deferred payment.
| Segment | FY2025 Revenue Share | Gross Margin (2023→2025) | 2026 First Three Quarters Volume/Price | Business Logic |
|---|---|---|---|---|
| New energy & new materials (DMC/dibasic acids/adipic acid/caprolactam/Nylon 6/BDO-NMP etc.) | 50.8% (RMB 15.557 billion) | 17.24%→13.07%→10.71%, three straight declines | Volume 2.5828 million tons, ASP +8.7% | Largest but thinnest profitability; most products oversupplied (DMC operating rate 54%, DMF 45%) |
| Chemical fertilizers (mainly urea) | 23.9% (RMB 7.306 billion) | 35.07%→29.90%→32.30% | Volume 4.0373 million tons, ASP +9.8% | Profit engine: FY2025 segment gross profit of RMB 2.360 billion, highest; 3.07 million tons capacity across two bases |
| Acetic acid & derivatives | 11.1% (RMB 3.387 billion) | 20.95%→27.62%→29.70% | Volume 1.0923 million tons, ASP +23.5% | 1.5 million tons capacity running full; industry operating rate 85%; largest beneficiary of this price rally |
| Organic amines (DMF/methylamines) | 7.7% (RMB 2.361 billion) | 12.87%→6.54%→14.19% | Volume 398,400 tons, ASP +13.7% | DMF global #1 with industry pricing power, but industry operating rate only 45% |
| Others | 6.5% (RMB 1.989 billion) | 27.23% (+5.43pp) | — | Low-margin ancillary business actively shrunk (-42.9%) |
The profit engine is chemical fertilizers, not the largest-by-revenue new materials segment: estimated by "revenue share × gross margin," FY2025 fertilizers contributed ~RMB 2.36 billion of gross profit (~37% of main-business gross profit), new materials ~RMB 1.67 billion, acetic acid ~RMB 1.01 billion. Gross margin spread across segments reaches 21.6 percentage points (fertilizers 32.30% vs new materials 10.71%): the former relies on coal-gasification–synthetic ammonia–urea integration with 110.9% capacity utilization, while the latter sits in oversupplied tracks like DMC/Nylon 6 dominated by price wars. In trend terms, the new materials segment's three straight gross margin declines signal declining unit profitability in the main expansion segment; even as its revenue share rose to 58.4% (9M2026), it dragged down the overall gross margin structure — this is a "volume-for-share" platform strategy whose success hinges on delivering the electronics/battery-grade premiumization.
Accounting red flags:
Cross-period consistency: ① New materials gross margin down three straight years — consistent with management's explanation of "overcapacity, prices oscillating at lows"; ② Top-five supplier concentration doubled in three years to 42.66% — consistent with the "point-to-point procurement, cost anchoring" strategy, but concentration risk is rising; ③ Interest-bearing debt rising three consecutive years (RMB 7.84 → 9.47 → 10.95 → 11.13 billion) while ROIC fell from 10.3% → 8.4% — levering up at the bottom, consistent with management's expansion strategy, but solvency metrics need monitoring.
Current market data and percentiles (2026-10-29 close): price RMB 19.48, market cap RMB 53.57 billion; PE(TTM) 13.07x (1-yr 11%/5-yr 47% percentile), PB 1.53x (1-yr 7%/5-yr 15%/10-yr 7% percentile, 13% per third-party data), PS 1.66x, dividend yield (TTM) 2.32%; EV RMB 61.91 billion, EV/EBITDA (2026E) ~7.2x, 8.0x on 2025A basis. Peer comparison:
| Company | PE(TTM) | PB | 2025 Revenue Growth | ROE | Key Difference |
|---|---|---|---|---|---|
| Hualu Hengsheng | 13.07 | 1.53 | -9.52% | 10.32% (2025 weighted) | 40+ product flexible co-production platform, low single-product exposure |
| Baofeng Energy | 9.75 | 2.87 | +45.64% | 24.84% | Single-track coal-to-olefins with own coal mines; earnings at cycle highs (PE at 0% 5-yr percentile = low PE at peak) |
| Luxi Chemical | 19.01 | 1.09 | -2.08% | Net margin only 3.1% | Also multi-product co-production but one notch weaker on cost control; PE inflated at trough (= high PE at trough) |
Baofeng and Luxi neatly illustrate both ends of the cyclical-stock PE trap (low PE at peak and high PE at trough). Hualu's TTM earnings sit at the upper-middle of the cycle and PE near the 5-year median — the "middle segment," a neutral percentile signal.
Market-implied expectations: Solving backwards on EV basis (ke 9.5%, perpetual +2.4%), the current price implies normalized earnings of ~RMB 4.0–4.4 billion; ~RMB 3.8 billion on equity basis. For comparison: company 9M annualized RMB 4.21 billion, 3-year ex-non-recurring average RMB 3.621 billion, Q3 single-quarter annualized RMB 3.26 billion, sell-side consensus 2026E RMB 4.81 billion — what the current price demands is neither the trough (RMB 3.26 billion) nor optimism (RMB 4.8 billion), but "~RMB 4.2 billion sustainable + low-single-digit perpetual growth." This judgment is sensitive to the discount rate (each ±50bp in ke moves implied earnings by ~8%–9%), and under the convention of zero perpetual growth for cyclical assets the conclusion shifts; it must be cross-checked against the PB basis.
Three-tier value (EPV): Asset value (floor) ~RMB 12.7/share (book-value-per-share basis; replacement cost undisclosed, book value used as proxy); EPV at zero growth ~RMB 10.5/share (sustainable FCFE ~RMB 1.0/share ÷ ke 9.5%: mid-cycle attributable profit of RMB 3.8 billion × cash conversion 1.25 − maintenance capex ~RMB 2.0 billion = FCFE ~RMB 2.75 billion); EPV range RMB 10.5–14.6 (FCFE RMB 0.73–1.16 × ke 8.5–10.5%), PB×ROE cross-check ~RMB 14.5; the residual of current price over the zero-growth EPV midpoint is ~RMB 9.0/share (~46%, or ~25% at the top of the EPV range) — nearly half the current price is a bet on "new capacity delivery + no cycle reversal." This residual has partial support in proven capacity-driven growth (Jingzhou's 2026H1 net profit of RMB 637 million as evidence), but it mixes capacity growth with cyclical repair; if spreads fall back in 2027, only incremental contributions from TDI and other projects (RMB 300–500 million) would provide a floor.
Three scenarios and odds (12 months):
| Scenario | Probability | Fair Range | vs. Current | Swing Factor |
|---|---|---|---|---|
| Bear | 25% | RMB 12.5–14.5 | -31% (midpoint) | Spreads fall back to 2024-25 lows + coal at RMB 750–800/ton: 2027E attributable profit RMB 2.7–3.0 billion × trough PE 12–13x (PB ~1.05–1.1x with asset-floor buffer) |
| Base | 50% | RMB 20–22 | +7.8% to +12.9% | Current earnings annualize to a sustainable RMB 4.2 billion + moderate new-capacity increment to RMB 4.4–4.8 billion × 13x (anchors: peers' 2026E consensus average 13x + own 5-yr PE median 13.25x + PB×ROE cross-check RMB 20.3) |
| Bull | 25% | RMB 26.5–30.5 | +46% (midpoint) | Anti-involution deepens + export volume + TDI full-run premium + widening oil-coal spread: 2027E RMB 5.2–5.6 billion × 14–15x |
Probability-weighted fair value ~RMB 21.0 (+7.8%), right-skewed distribution (bear -31%/bull +46%). Anchoring for the base case's 13x exit multiple: peers' 2026E Wind consensus average of 13x, own 5-year PE(TTM) median of 13.25x, and 10-year median of 14.52x — mutually corroborating and independent of current multiples; the bear case is constructed on independent stress assumptions (spreads back to 2025 lows + high coal prices). Within the search window, no sell-side target price sits below the current price (most cautious being CICC's 2026-08-21 target of RMB 25.3 on 2026E of RMB 4.21 billion); there is a gap in external bearish coverage, so the bear case does not adopt external estimates as the floor anchor.
This report's earnings forecast (reconciliation anchor):
| Period | Revenue | Attributable Net Profit | Key Assumptions |
|---|---|---|---|
| FY2026E | RMB 34.0–34.5 billion | RMB 4.1–4.25 billion (EPS RMB 1.49–1.55) | Q4 attributable profit RMB 0.93–1.08 billion: post-maintenance restart + gasification platform cost cuts + winter restocking peak vs rising coal prices; revenue 1.5%–3% above guidance (RMB 33.5 billion) |
| FY2027E | RMB 35.8–37.2 billion | RMB 4.4–4.8 billion (EPS RMB 1.60–1.75) | Increments = urea +750,000 tons + full output of dibasic/oxalic acids + full-year gasification platform contribution; deductions = price pressure from coal-chemical capacity expansion; 11%–18% below sell-side consensus (RMB 5.39 billion) |
Conclusion: reasonably undervalued, not deeply cheap. The fit between quality (leftmost cost position + earnings quality + dual-base replication) and price (low PB percentile + undiluted implied expectations) is good, but this is not deep mispricing: the margin of safety is only ~3% (base-case fair-value floor of RMB 20 vs current RMB 19.48, precisely +2.7%); the odds structure is positively skewed but with a deep left tail. Suitable as a core value anchor position; aggressive adding should wait for Q4 spread resilience to be validated.
Industry Definition and Market Size: Hualu's track is "traditional coal chemicals (synthetic ammonia–urea, acetic acid, organic amines) + coal-based new materials (nylon chain, battery materials chain)", sharing the same coal source as Baofeng's coal-to-olefins (modern coal chemicals) but on different value chains. By volume, market size: urea domestic apparent consumption in 2025 was 67.60 million tonnes (7-year CAGR +4.7%), equivalent to roughly a RMB 120 billion market at the 2026Q2 average price of RMB 1,869/tonne; acetic acid apparent consumption 9.74 million tonnes (7-year CAGR +5.0%), roughly RMB 28 billion; the high-growth new energy materials chain—oxalic acid 2025 apparent consumption 493,000 tonnes (4-year CAGR +28.6%), DMC 1.65 million tonnes (4-year CAGR +33.1%). The structural incremental demand chain is clear: lithium iron phosphate and energy storage ramp-up → rising volume and price for electrolyte solvents (DMC/EC) and oxalic acid used in high-compaction LFP → the company's share in this track (oxalic acid ~45%, ranking first; DMC capacity of 600,000 tonnes, No. 1 nationally; electronic-grade purity of 99.995% supplied directly to leading electrolyte producers). Based on a "driver × penetration × share" estimate: if oxalic acid demand sustains 20%+ growth, 2027 demand of ~700,000 tonnes ≈ the company's existing capacity; the company, positioned on the left side of the cost curve, captures half of industry incremental volume (~+50,000 tonnes/year) × a spread of ~RMB 2,500/tonne ≈ +RMB 125 million gross profit per year—the increment is real but relative to the RMB 4.2 billion profit base it remains a second curve, not yet at a re-rating level.
Value Chain and Value Distribution: Upstream is feedstock coal/thermal coal (market-based procurement; 2026Q2 Shenmu 6500-kcal pit-head price ~RMB 1,057/tonne, +13% YoY; coal supply is highly concentrated and coal chemicals players have weak bargaining power upstream); midstream coal gasification into syngas → synthetic ammonia/methanol is the watershed for cost and energy consumption (Hualu has the industry's lowest per-tonne ammonia cost; after the gasification platform upgrade, comprehensive energy consumption fell another ~5%; obsolete gasification such as fixed-bed faces forced exit under energy-efficiency benchmark constraints); downstream is a commodity buyer's market spanning fertilizers/solvents/polyester chain/nylon/lithium batteries/coatings. Gross profit mainly accrues at the intersection of "low-cost syngas platform × high-margin product switching"—in 2025H1 fertilizers contributed 41% of gross profit and new materials 48% of revenue; switching on the same platform by profitability is the mechanism for maximizing retention.
Supply-Demand and Competitive Landscape: 2025 marked the bottom of comprehensive oversupply in traditional coal chemicals (most small and mid-sized urea, acetic acid, adipic acid, octanol, organic amine, and caprolactam producers were loss-making; Hualu preserved cash flow via thin profits on low costs); 2026 shifted into recovery, driven by a three-factor resonance of "oil price shock + urea export resumption (Jan–Jul exports +40.7%, June export guidance price abolished) + anti-involution (NDRC controlling incremental capacity, MIIT promoting exit, caprolactam industry self-discipline cutting output ~20%)". Supply-side policy caps: urea constrained by capacity-swap rules, no new DMF capacity in the next two years, caprolactam self-discipline output cuts, oxalic acid adding only +200,000 tonnes over two years—the under-construction/existing ratio for traditional products is at a historical low; however, DMC supply is still growing fast (4-year capacity CAGR +34.2%, industry utilization ~49%–57%), and the long-term large-scale expansion of modern coal chemicals in Xinjiang (coal-to-oil under construction/planned 11.72 million tonnes, coal-to-gas 30 billion cubic meters, coal-to-olefins 14.35 million tonnes, total investment over RMB 800 billion, concentrated commissioning after 2027) constitutes systematic long-term suppression. Concentration: urea is highly fragmented (Hualu's 3.07 million tonnes ~4.5% of national total; first-tier Yangmei/China Coal at the 2-million-tonne level); acetic acid—Hualu 1.5 million tonnes, No. 1 nationally (9.6%); DMF global No. 1 (~26%); oxalic acid 45%, No. 1. Entry barriers: dual-control of energy consumption and "two-high" approvals (projects exceeding 500,000 tonnes of standard coal require NDRC review), capacity swaps, water resource and carbon emission constraints, and capital and technology accumulation—policy barriers are extremely high and continue to strengthen.
Cycle and Regulation: The industry is in a "right of the bottom, gradual tight-balance recovery" phase (cycle timing detailed in next chapter). Regulation is broadly favorable to Hualu: energy-efficiency benchmarks + two-high constraints raise entry thresholds and accelerate fixed-bed exit (reinforcing Hualu's left-side position on the cost curve); abolition of the urea export guidance price (2026-06) improves price elasticity; fertilizer supply security and price stabilization policies periodically restricting exports during spring planting are a policy disturbance item.
Peer Benchmarking:
| Company | 2025 Revenue | 2025 Net Profit Attrib. | Gross Margin | ROE/Net Margin | Key Differences vs. Hualu |
|---|---|---|---|---|---|
| Hualu Hengsheng | RMB 30.969 bn | RMB 3.315 bn | 19.16% | 10.32% | 40+ products with flexible co-production, cycle-resistant; expense ratio 3–5%, industry's lowest |
| Baofeng Energy | RMB 48.038 bn | RMB 11.350 bn | 35.92% | 24.84% | Single-track coal-to-olefins + own coal mines; elasticity and growth far exceed Hualu but product mix is narrow |
| Luxi Chemical | RMB 29.143 bn | RMB 907 million | 11.0% | Net margin 3.1% | Also multi-product co-production, but new materials asset losses drag and cost control is a tier weaker |
| Hubei Yihua | RMB 25.653 bn | RMB 809 million | Urea segment 13.95% | — | Resource-based diversification (phosphate/coal mines); urea gross margin only 14% vs. Hualu's fertilizer 32.3% |
Company Positioning: A leader on the far left of the cost curve with a rising share trend (2025 fertilizer sales +22%, new materials sales +18%). Sources of moat = gasification technology and energy consumption metrics (policy-driven exit actually reinforces its relative position) × flexible multi-product co-production switching capability × extreme engineering and expense management × replicable dual-base model. Share data note: the company's product share figures (DMF 26%, acetic acid 9.6%, oxalic acid 45%) are compiled from sell-side research; differences versus industry association definitions have not been independently verified by third parties, and the oxalic acid 45% figure and DMC capacity No. 1 status carry overlapping-definition risk; this report cites the sell-side definitions with disclosure.
Historical Cycle Template (urea/coal-based product price basis): ① 2014–2016 capacity oversupply bottom—urea capacity 87 million tonnes, oversupply ~25 million tonnes; prices RMB 1,350–1,380/tonne in 2014 and RMB 1,200/tonne in 2016, below cost, with 80%+ of companies loss-making; supply-side reform and environmental exit removed 8.93 million tonnes (duration ~3 years); ② 2021 super peak—dual energy-consumption control + surging coal prices pushed prices to record highs; the company's 2022 net profit attributable of RMB 6.289 billion and weighted ROE of 25.58% were recent-cycle peaks; ③ 2022–2025 downcycle bottoming—falling coal prices + new capacity after swaps + weak real-estate-chain demand; 2025 spreads for most products at historical lows (urea futures down a cumulative -28.9% from RMB 2,467/tonne in Sep 2022); ④ 2026 recovery phase—oil price shock + exports + anti-involution. A full cycle lasts ~4–5 years; currently in the early-to-middle stage of phase ④.
Current Percentile Position: Urea futures main contract at RMB 1,716/tonne (2026-10-29) is at the 21st percentile of its 52-week range and has rebounded from the 2025H1 spot low of RMB 1,450/tonne; ethylene glycol +40% YTD (64th percentile over 52 weeks); acetic acid 2026Q2 average price RMB 3,229/tonne (+19% QoQ); caprolactam RMB 12,077/tonne (+15% QoQ)—mainstream products have rebounded 15%–30% from bottoms, in the 20%–40% historical percentile range, none overheated. Hualu's own earnings: RMB 3.315 billion in 2025 (trough) → ~RMB 4.2 billion annualized in 2026 (mid-recovery) vs. RMB 6.289 billion in 2022 (peak)—currently at roughly the 30%–40% position of the cycle.
Supply Response: Traditional coal chemicals are policy-capped (urea swaps, no new DMF capacity for two years, CPL self-discipline cut of 20%), with under-construction/existing ratios at historical lows; the real supply wave is Xinjiang's modern coal chemicals after 2027 (2–3 year construction cycles, average annual investment over RMB 160 billion over the next 5 years)—a long-term suppression but not within the 12-month window. The company's own 2026–2028 commissioning: battery-grade EC 50,000 tonnes (2026; commissioning announcement not yet seen, timing to be verified), urea +750,000 tonnes (27H1), gasification platform upgrade (commissioned), TDI 300,000 tonnes (mechanical completion end-2027, production early 2028).
Through-Cycle Earnings: Normalized (mid-cycle) attributable net profit of RMB 3.6–4.0 billion, midpoint RMB 3.8 billion (last 3 years' adjusted: 3.703/3.870/3.288 billion + 9M2026 annualized 4.21 billion; excluding the 2021–22 super cycle and 2026 geopolitical spreads), EPS RMB 1.38; normalized P/E anchor 12–14x (comparables 2026E consensus average 13x + own 5-year median 13.25x) → normalized value RMB 16.6–19.3; ±5x sensitivity range RMB 9.7–26.3 (7–9x for trough earnings, 18–20x for upper-boom). Trough EPS RMB 1.18–1.20 (cross-validated by two genuine trough candidates: 2025 adjusted profit of RMB 3.288 billion and 2026Q3 single-quarter annualized RMB 3.256 billion), deep-stress scenario RMB 0.98–1.09 (spreads back to 2024–25 lows + coal at RMB 750–800/tonne, attributable profit RMB 2.7–3.0 billion). Current TTM of RMB 4.112 billion is at the upper edge of mid-cycle, PE 13.07x ≈ 5-year median—this is "mid-cycle", without the peak-low-PE trap characteristic (in 2022, the lowest PE of 6.94x occurred during the RMB 6 billion+ earnings period, not comparable this round). Asset value floor: book value per share ~RMB 12.7 + 27.2% low leverage ratio.
Downside Stress Test: Based on 9M2026 (static, no flexible co-production buffer): product prices -10% → 9M attributable profit falls to ~RMB 1.16 billion (-RMB 2.01 billion); -20% → the whole company turns loss-making (~-RMB 890 million)—earnings sensitivity to price is extremely high; the premise for still earning RMB 3.3 billion in 2025 was coal prices being simultaneously low; the "prices back to 2025, coal prices staying high" two-sided squeeze is precisely the core of the deep-stress scenario. In the trough scenario (total profit ~RMB 1.8 billion), net interest-bearing debt/EBITDA rises to ~2.0x and interest coverage ~6.4x—solvency is safe but dividends and valuation come under pressure; trough valuation band: RMB 1.7 billion × 15–20x = RMB 25.5–34.0 billion (RMB 9.3–12.4) combined with PB 1.15–1.3x (RMB 14.9–16.9, on book value per share of RMB 12.7–13.0) → RMB 11.5–16 overall.
Management's Cycle Discipline: Judged as "counter-cyclical expansion at the bottom + no dividend cuts"—CapEx fell from a peak of RMB 8.7 billion (2023) to RMB 3.65 billion, yet during the 2024–2025 earnings downturn it still launched a new gasification platform (RMB 3.039 billion) and completed projects such as BDO/NMP, while maintaining a ~32% payout ratio + buybacks, with no equity financing at highs; counter-cyclical deployment (Jingzhou Phase I commissioned at the 2023 cycle bottom, gasification platform commissioned in 2026) is a plus on cycle discipline, at the cost of leverage rising for three consecutive years.
Overall View: Neutral, confidence 0.55, time horizon 12 months. Hualu Hengsheng is a scarce "lowest cost + earnings quality + platform replication" triple-verified name in the A-share chemicals sector; current valuation (low PB percentile + implied expectations not stretched) matches its quality well, but three factors cap the rating: ① Q4 spread validation not yet landed (the squeeze from rising coal prices + weakening urea is underway); ② margin of safety is only ~+2.7%, odds are positively skewed but the left tail is deep (bear case -31%); ③ growth options account for ~25%–46% of the current price, with key TDI estimates relying on a single sell-side source. Strategy: the current price suits use as a core-position value anchor (TTM dividend yield 2.32% + ~32% payout ratio provide a floor); add-position signals are Q4 single-quarter attributable profit ≥ RMB 1.0 billion or coal prices falling below RMB 900/tonne; if the share price breaks below RMB 16.5 (PB ~1.3x), re-assess whether the valuation anchor should shift down toward the trough band (RMB 11.5–16). Risk Alerts: spread decline, Xinjiang long-term supply, DMC oversupply, RMB 658 million litigation recovery, bank acceptance bill collections and rising leverage. Catalysts: 2026 annual report (2027-03), urea +750,000 tonnes commissioning (27H1), TDI milestones (within 2027), urea export quotas and deepening anti-involution.
Data and definitions note: price anchor is the 2026-10-29 closing price of RMB 19.48 (frozen); financial data as of the 2026 Q3 report (disclosed 2026-10-30); segment and volume/price data from company periodic reports and operating data announcements; industry and peer data from sell-side research and public sources (as noted); earnings forecasts and scenario valuations in this report are independent estimates, not company guidance.